Kristin Peck
Kristin Peck is Chief Executive Officer and serves on the Board of Zoetis, the world’s leading animal health company and a member of the Fortune 500. With more than 20 years of experience in life sciences and animal health, Ms. Peck is a purpose-driven leader passionate about driving growth through innovation, superior customer experience and colleague empowerment.
Since becoming CEO in 2020, Ms. Peck has guided Zoetis through a volatile macro environment to deliver superior financial growth – with average organic operating topline growth rates that have outpaced both industry growth and historic company performance. Under her leadership, the company’s portfolio has grown to include 18 blockbuster products – and Zoetis has established a robust pipeline with 12 more potential blockbusters (products with expected future potential sales of $100M+) on the horizon – in addition to delivering industry-leading operating margins.
Ms. Peck’s transformative leadership has earned significant distinctions, including being named to the TIME100 Health (2025), CNBC Changemakers (2024), Barron’s Top CEOs (2022) lists and being recognized as a Fortune Businessperson of the Year (2020).
Before joining Zoetis, Ms. Peck served as Executive Vice President, Worldwide Business Development and Innovation, at Pfizer Inc. and as a member of Pfizer's Executive Leadership Team. Earlier in her career, Ms. Peck held roles at Boston Consulting Group, as well as in private equity and real estate finance at The Prudential Realty Group, The O'Connor Group and J.P. Morgan.
Ms. Peck serves on the boards of BlackRock (NYSE: BLK), Mayo Clinic, and Business Roundtable.
She earned a bachelor's degree from Georgetown University and an MBA from Columbia Business School.
Zoetis
Website: www.zoetis.com
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees.
For more information, visit www.zoetis.com
